生物学药物对控制不充分的喘患者的比较疗效:一个网络元分析
Hayeon Kim1, Myeong Gyu Kim2, Sung-Ryeol Kim3
1College of Pharmacy, Korea University, Sejong, Republic of Korea.
The World Allergy Organization journal
|August 2, 2024
概括
与安慰剂相比,生物药物显著改善了喘控制. 特定的生物制剂,如dupilumab和tezepelumab在某些喘表型中表现出优越的疗效,有助于治疗选择.
科学领域:
- 肺部病理学 肺部病理学
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘管理对患有不充分控制疾病的患者来说仍然具有挑战性.
- 对抗喘的生物药物的比较疗效需要进一步研究.
- 网络元分析为比较多种治疗方法提供了一个强大的框架.
研究的目的:
- 进行一个网络元分析,比较各种生物药物对喘的疗效.
- 在患有难以控制喘的患者中,评估生物药物与安慰剂以及彼此之间的比较.
主要方法:
- 在主要数据库 (PubMed,Embase,Web of Science,Scopus) 中对随机对照试验 (RCT) 的系统搜索.
- 包括在2022年1月6日之前发表的RCT,评估生物药物与安慰剂或其他生物药物的对比.
- 结果包括喘恶化率 (AER),支气管扩展前1秒内强制呼吸量 (preBD FEV1),喘控制问卷 (ACQ) 和喘生活质量问卷 (AQLQ).
- 使用随机效应模型的频率网络元分析.
主要成果:
- 分析了23个涉及8376名参与者的RCT.
- 所有生物药物在AER,preBD FEV1和ACQ方面都比安慰剂显著改善.
- 在患有≥300细胞/μL或eosinophilic喘的患者中,dupilumab和tezepelumab与抗IL-5药物相比显示出优异的preBD FEV1改善.
- 与安慰剂相比,本拉利祖马布 (但不是reslizumab) 显著改善了ECQ和AQLQ结局,在患有≥300个细胞/μL的乙氨基酸细胞计数的患者中.
结论:
- 生物药物为患有控制不良喘的患者提供了显著的好处.
- 以表型和生物标志物为指导的生物选择可以优化治疗结果.
- 与抗IL-5疗法相比,杜皮卢马布和特泽佩卢马布可能对特定的异性喘表型更有效.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
264
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
264
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
233
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
233
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
244
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
244
01:19Antiasthma Drugs: Leukotriene Modifiers
268
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
268
01:17Drugs Used in Lower Respiratory Disorders: Overview
386
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
386
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K